TW202325728A - 治療阿茲海默症之方法 - Google Patents
治療阿茲海默症之方法 Download PDFInfo
- Publication number
- TW202325728A TW202325728A TW111142020A TW111142020A TW202325728A TW 202325728 A TW202325728 A TW 202325728A TW 111142020 A TW111142020 A TW 111142020A TW 111142020 A TW111142020 A TW 111142020A TW 202325728 A TW202325728 A TW 202325728A
- Authority
- TW
- Taiwan
- Prior art keywords
- tau
- plasma
- antibody
- human subject
- dose
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163275442P | 2021-11-03 | 2021-11-03 | |
| US63/275,442 | 2021-11-03 | ||
| US202163277127P | 2021-11-08 | 2021-11-08 | |
| US63/277,127 | 2021-11-08 | ||
| US202263309796P | 2022-02-14 | 2022-02-14 | |
| US63/309,796 | 2022-02-14 | ||
| US202263343029P | 2022-05-17 | 2022-05-17 | |
| US63/343,029 | 2022-05-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202325728A true TW202325728A (zh) | 2023-07-01 |
Family
ID=86241855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111142020A TW202325728A (zh) | 2021-11-03 | 2022-11-03 | 治療阿茲海默症之方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240425573A1 (https=) |
| EP (1) | EP4426349A4 (https=) |
| JP (1) | JP2024540294A (https=) |
| TW (1) | TW202325728A (https=) |
| WO (1) | WO2023081194A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025240753A1 (en) * | 2024-05-16 | 2025-11-20 | Creative Bio-Peptides, Inc. | Peptides and therapies for treating neurological disorders |
| CN118777453B (zh) * | 2024-06-25 | 2025-04-08 | 上海交通大学医学院附属瑞金医院 | 一种基于液相色谱-串联质谱定量分析血液中仑卡奈单抗浓度的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20140049T1 (hr) * | 2007-01-05 | 2014-02-28 | University Of Zürich | Anti beta-amiloid antitijela i njihova upotreba |
| EP2560681A4 (en) * | 2010-04-22 | 2013-09-25 | Janssen Alzheimer Immunotherap | USE OF TAU FOR MONITORING IMMUNOTHERAPY |
| WO2014011972A1 (en) * | 2012-07-13 | 2014-01-16 | Bristol-Myers Squibb Company | Tau immunoassay |
| NZ630542A (en) * | 2012-08-16 | 2017-06-30 | Ipierian Inc | Methods of treating a tauopathy |
| WO2021016466A1 (en) * | 2019-07-24 | 2021-01-28 | Duke University | Compositions and methods for the diagnosis and treatment of alzheimer's disease |
| KR20220084095A (ko) * | 2019-10-22 | 2022-06-21 | 바이오젠 엠에이 인코포레이티드 | 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체 |
-
2022
- 2022-11-02 WO PCT/US2022/048684 patent/WO2023081194A2/en not_active Ceased
- 2022-11-02 JP JP2024526586A patent/JP2024540294A/ja active Pending
- 2022-11-02 EP EP22890708.5A patent/EP4426349A4/en active Pending
- 2022-11-02 US US18/707,366 patent/US20240425573A1/en active Pending
- 2022-11-03 TW TW111142020A patent/TW202325728A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4426349A2 (en) | 2024-09-11 |
| WO2023081194A3 (en) | 2023-10-26 |
| EP4426349A4 (en) | 2025-10-29 |
| JP2024540294A (ja) | 2024-10-31 |
| US20240425573A1 (en) | 2024-12-26 |
| WO2023081194A2 (en) | 2023-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220372123A1 (en) | Anti-beta-amyloid antibody for treating alzheimer's disease | |
| US20220281963A1 (en) | Methods for treating alzheimer's disease | |
| JP2020055880A (ja) | アルツハイマー病の治療法 | |
| TW202317192A (zh) | 用於阿茲海默氏症治療的生物標記物 | |
| TW202325728A (zh) | 治療阿茲海默症之方法 | |
| TW202334201A (zh) | 抗Tau抗體之組成物、劑型及方法 | |
| KR20240142535A (ko) | P-tau181 수준을 사용한 치료 방법 | |
| CN120583962A (zh) | 抗N3pGluβ淀粉样蛋白抗体、其剂量及其用途 | |
| KR20250114372A (ko) | 타우(tau) pet 수준을 이용하는 치료 방법 | |
| US20250051427A1 (en) | Methods of using an anti-amyloid beta protofibril antibody and anti-tau antibody | |
| CN120826223A (zh) | 鲨肌醇与免疫治疗剂组合用于治疗阿尔茨海默氏病 | |
| US20240270830A1 (en) | Methods for treating alzheimer's disease | |
| CN118829445A (zh) | 用于治疗阿尔茨海默病的方法 | |
| Krick et al. | A Change of Mind: Targeting Amyloid-β with Better Safety Profile | |
| WO2025240435A1 (en) | Methods of treating neurological disorders with anti-abeta antibodies | |
| WO2026057816A1 (en) | Treatment of tauopathies with tau-binding antibodies | |
| EA052963B1 (ru) | Способы применения антитела к протофибриллам бета-амилоида и антитела к тау-белку | |
| NZ788486A (en) | Methods for treating Alzheimer's disease |